Regulator finds advertising of complementary product “misleading”
BMJ 2006; 333 doi: https://doi.org/10.1136/bmj.39044.539097.DB (Published 30 November 2006) Cite this as: BMJ 2006;333:1141
- Bob Burton
- 1Canberra
The Australian regulator of the drug industry has found that the company Schwabe Pharma (Australia) breached standards for media advertisements when it promoted the complementary medicine Tebonin.
Tebonin, which is an extract of ginkgo biloba, is manufactured by the German company Dr Willmar Schwabe, which claims that eight million Tebonin pills are consumed globally each day.
In July, the company's Australian subsidiary managed to suppress publication of a report by AusPharm Consumers Health Watch, a …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.